Evidence map›Paper›PMID 27641427›Full record

ReviewStem cells (Dayton, Ohio)2017

Concise Review: Liver Regenerative Medicine: From Hepatocyte Transplantation to Bioartificial Livers and Bioengineered Grafts.

Clara T Nicolas, Raymond D Hickey, Harvey S Chen, Shennen A Mao, Manuela Lopera Higuita, Yujia Wang, Scott L Nyberg

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Stem cells (Dayton, Ohio), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 1 pooled it
16.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 1 synthesis or guideline pooled it, 125 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. The future of hepatology.Hepatology (Baltimore, Md.) · 2023
    Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. A Brief History of Hepatic Encephalopathy.Clinical liver disease · 2021
    Review
  15. Liver Organoids: Formation Strategies and Biomedical Applications.Tissue engineering and regenerative medicine · 2021
    Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Experimental and therapeutic medicine · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Clara T NicolasWilliam J Von Liebig Transplant Center, Mayo Clinic, Rochester, Minnesota, USA.
Raymond D HickeyDepartment of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Harvey S ChenDepartment of Surgery, Mayo Clinic, Rochester, Minnesota, USA.
Shennen A MaoDepartment of Surgery, Mayo Clinic, Rochester, Minnesota, USA.
Manuela Lopera HiguitaDepartment of Physiology and Biomedical Engineering, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
Yujia WangWilliam J Von Liebig Transplant Center, Mayo Clinic, Rochester, Minnesota, USA.
Scott L NybergWilliam J Von Liebig Transplant Center, Mayo Clinic, Rochester, Minnesota, USA.
Mayo Clinic in Florida · USMayo Clinic · USMayo Clinic in Arizona · US

Funding

Immunodeficient FAH-/- PigsR01DK106667 · NIDDK · MAYO CLINIC ROCHESTER · PI NYBERG, SCOTT L · 2015 to 2019
$2.1M
XENOGENEIC BIOARTIFICAL LIVERR01DK056733 · NIDDK · MAYO CLINIC ROCHESTER · PI NYBERG, SCOTT L · 1999 to 2010
$1.4M
FAH-Deficient PigsR41DK092105 · NIDDK · YECURIS CORPORATION · PI NYBERG, SCOTT L · 2011 to 2011
$212k
NIDDK NIH HHS R01 DK056733NIDDK NIH HHS R01 DK106667NIDDK NIH HHS R41 DK092105
6 · The paper itself

Abstract

Donor organ shortage is the main limitation to liver transplantation as a treatment for end-stage liver disease and acute liver failure. Liver regenerative medicine may in the future offer an alternative form of therapy for these diseases, be it through cell transplantation, bioartificial liver (BAL) devices, or bioengineered whole organ liver transplantation. All three strategies have shown promising results in the past decade. However, before they are incorporated into widespread clinical practice, the ideal cell type for each treatment modality must be found, and an adequate amount of metabolically active, functional cells must be able to be produced. Research is ongoing in hepatocyte expansion techniques, use of xenogeneic cells, and differentiation of stem cell-derived hepatocyte-like cells (HLCs). HLCs are a few steps away from clinical application, but may be very useful in individualized drug development and toxicity testing, as well as disease modeling. Finally, safety concerns including tumorigenicity and xenozoonosis must also be addressed before cell transplantation, BAL devices, and bioengineered livers occupy their clinical niche. This review aims to highlight the most recent advances and provide an updated view of the current state of affairs in the field of liver regenerative medicine. Stem Cells 2017;35:42-50.

Indexed as

Liver, ArtificialAnimalsBioengineeringHepatocytesHumansLiver RegenerationRegenerative MedicineStem CellsBioartificial liverCell therapyCell transplantationLiver regenerationTissue engineering

Identifiers

PMID27641427
PMCPMC5529050
OpenAlexW2529832034

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.